West Pharmaceutical reports Q2 EPS $2.11, consensus $1.93

Reports Q2 revenue $753.8M, consensus $756.53M. “We had a solid first-half of 2023, and with the momentum of our high-value product capacity expansion projects, we are well positioned for an even better second-half of the year,” said Eric Green, president, CEO and chair of the board. “While COVID-19 related sales continued to decline as expected, our base Proprietary Products business again organically grew double digits. We see continued stability in both near- and long-term demand trends for our HVP components, devices and systems, and our team members remain focused on creating value-added solutions for our customers.”